diffuse large b cell lymphoma dlbcl cell line  (ATCC)

Journal: Cancers

Article Title: Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach.

doi: 10.3390/cancers14194691

Figure Lengend Snippet: Figure 1. Evaluation of cell viability after isoform-specific- and pan-BET inhibition in Burkitt‘s lymphoma and diffuse large B-cell lymphoma cell lines. Burkitt‘s lymphoma (BL) cell lines (a) DG-75 and (b) RAJI; and diffuse large B-cell lymphoma (DLBCL) cell lines (c) SU-DHL-4 and (d) U-2946 were exposed to serial-diluted isoform-specific inhibitor AZD5153 or pan-BET inhibitor I-BET151 (0.001 µM–10 µM). Cell proliferation was determined by trypan blue staining and metabolic activity by WST-1 assay 24 h, 48 h and 72 h after exposure. Data are presented as the mean ± SD. Statistical significance was calculated by one-way ANOVA followed by Dunnett’s multiple comparison test as post hoc analysis. The Kruskal–Wallis test was applied to non-parametric data. Statistical significance is displayed as * p < 0.033, ** p < 0.002, *** p < 0.001 versus control group (n ≥3).

Article Snippet: Human Burkitt’s lymphoma (BL) cell lines DG-75 and RAJI and diffuse large B-cell lymphoma (DLBCL) cell lines SU-DHL-4 (GCB) and U-2946 (ABC) were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany), cultured as recommended by the manufacturer in RPMI 1640 media (Biochrom, Berlin, Germany) supplemented with 10% heat-inactivated FCS (Biochrom, Berlin, Germany) and 100 μg/mL penicillin and streptomycin (Biochrom, Berlin, Germany).

Techniques: Inhibition, Staining, Activity Assay, WST-1 Assay, Comparison, Control

Journal: Cancers

Article Title: Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach.

doi: 10.3390/cancers14194691

Figure Lengend Snippet: Figure 2. Simultaneous BET and SYK inhibition affected cell viability of BL and DLBCL cell lines synergistically. Cells were exposed to 1 µM Ento, 0.01 µM AZD or 0.1 µM I-BET as a single agent or in combination. Cell proliferation and metabolic activity were assessed in (a) BL cell lines (DG-75 and RAJI) and (b) DLBCL cell lines (SU-DHL-4 and U-2946) after 72 h. (c) Bliss calculations were based on proliferation. Synergistic effects of both combinations were calculated with a Bliss Independence model (EA+EB–EAEB). A value ∆= 0, >0 and <0 defines an additive-, synergistic- or antagonistic interaction, respectively. Data are presented as the mean ± SD. Statistical significance of cell viability data was calculated by one-way ANOVA followed by Tukey’s multiple comparison test as a post hoc analysis and displayed as * p < 0.033, ** p < 0.002, *** p < 0.001 versus control group and further versus the respective single agents (dashed line) (n ≥3).

Article Snippet: Human Burkitt’s lymphoma (BL) cell lines DG-75 and RAJI and diffuse large B-cell lymphoma (DLBCL) cell lines SU-DHL-4 (GCB) and U-2946 (ABC) were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany), cultured as recommended by the manufacturer in RPMI 1640 media (Biochrom, Berlin, Germany) supplemented with 10% heat-inactivated FCS (Biochrom, Berlin, Germany) and 100 μg/mL penicillin and streptomycin (Biochrom, Berlin, Germany).

Techniques: Inhibition, Activity Assay, Comparison, Control

Journal: Cancers

Article Title: Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach.

doi: 10.3390/cancers14194691

Figure Lengend Snippet: Figure 3. Morphological characterization after BET and SYK inhibition. Cells were exposed to 1 µM Ento, 0.01 µM AZD or 0.1 µM I-BET as a single agent or in combination. Representative light microscopy images of exposed cells after 72 h incubation. Cytospins were stained with May– Grunwald Giemsa stain (Pappenheim method). Light microscopy images (×100) revealed only moderate morphological changes in (a) BL cell line DG-75 and (b) DLBCL cell line SU-DHL-4.

Article Snippet: Human Burkitt’s lymphoma (BL) cell lines DG-75 and RAJI and diffuse large B-cell lymphoma (DLBCL) cell lines SU-DHL-4 (GCB) and U-2946 (ABC) were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany), cultured as recommended by the manufacturer in RPMI 1640 media (Biochrom, Berlin, Germany) supplemented with 10% heat-inactivated FCS (Biochrom, Berlin, Germany) and 100 μg/mL penicillin and streptomycin (Biochrom, Berlin, Germany).

Techniques: Inhibition, Light Microscopy, Incubation, Staining, Giemsa Stain